Clinical TrialJun 24, 2026, 08:30 AM
AIM ImmunoTech Highlights Ampligen Pancreatic Cancer Progress
AI Summary
AIM ImmunoTech Inc. highlighted significant progress in its Ampligen pancreatic cancer development program, including the early completion of Phase 2 DURIPANC study enrollment and positive interim clinical updates. The company anticipates key milestones, with primary endpoint analysis expected in December 2026 and topline results in the first quarter of 2027. AIM believes these advancements position Ampligen for potential late-stage development and represent a critical value-inflection period for the company.
Key Highlights
- Completed Phase 2 DURIPANC enrollment ahead of schedule.
- Dosed the final patient in the DURIPANC study.
- Reported positive interim clinical updates from DURIPANC.
- Primary endpoint analysis for DURIPANC anticipated December 2026.
- Topline DURIPANC results expected in Q1 2027.
- Progression-free and overall survival assessments expected June 2027.
- Maintained orphan drug designation for pancreatic cancer in major markets.
- Strengthened global intellectual property protection for Ampligen.
Price Impact
More from AIM